# Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis

> **NCT07546552** · NA · RECRUITING · sponsor: **Peter Humaidan** · enrollment: 100 (estimated)

## Conditions studied

- Female Infertility
- NF-κB Ligand
- RANKL
- Osteoporosis
- Follicle Development

## Interventions

- **OTHER:** Denosumab
- **OTHER:** PBS

## Key facts

- **NCT ID:** NCT07546552
- **Lead sponsor:** Peter Humaidan
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2028-03-15
- **Final completion:** 2028-03-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07546552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07546552, "Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07546552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*